Heptares is a clinical-stage company creating novel medicines targeting G protein-coupled receptors (GPCRs), a superfamily of receptors linked to a wide range of human diseases. Our proprietary StaR® technology and structure-based drug design (SBDD) capabilities are enabling us to build an exciting pipeline of new medicines with potential to transform the treatment of Alzheimer’s disease, schizophrenia, cancer, migraine, metabolic disease, and other indications. Our ability to address highly validated, yet historically undruggable, GPCRs has also attracted multiple pipeline and technology partners including Allergan, AstraZeneca, Kymab, Morphosys, Pfizer and Teva.

Heptares is a wholly owned subsidiary of Sosei Group Corporation.

Latest News

Jun 29, 2016
Heptares and leadXpro Enter Collaboration on Powerful New Approaches to GPCR Structure Determination for Drug Discovery
May 26, 2016
Hart-Scott-Rodino Clearance for Global Collaboration between its Subsidiary Heptares Therapeutics and Allergan

Jun 28 - Jul 1, 2016
17th Tetrahedron Symposium
Barcelona, Spain
Presenting: Miles Congreve

Aug 21-24, 2016
American Chemical Society National Meeting
Philadelphia, PA, USA
Presenting: Andrea Bortolato

© 2012-2016 Heptares Therapeutics